CN103405430A - Applications of corynoxine - Google Patents
Applications of corynoxine Download PDFInfo
- Publication number
- CN103405430A CN103405430A CN2013103949131A CN201310394913A CN103405430A CN 103405430 A CN103405430 A CN 103405430A CN 2013103949131 A CN2013103949131 A CN 2013103949131A CN 201310394913 A CN201310394913 A CN 201310394913A CN 103405430 A CN103405430 A CN 103405430A
- Authority
- CN
- China
- Prior art keywords
- nuoxin
- blood pressure
- corynoxine
- hypertension
- applications
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the technical field of medicines, and relates to applications of Chinese traditional herb monomer chemical corynoxine for resisting hypertension, and a corynoxine-containing composition used for preventing and treating hypertension.
Description
Technical field
The invention belongs to medical technical field, relate to the purposes of Ke Nuoxin.
Background technology
Hypertension is modal chronic disease, is also the topmost risk factor of cardiovascular and cerebrovascular disease, and apoplexy, myocardial infarction, heart failure and chronic kidney disease are its major complications.Both domestic and external facts have proved, hypertension are the diseases that can prevent and control, reduce hyperpietic's blood pressure level, can obviously reduce apoplexy and the events of heart attack, significantly improve patient's life quality, effectively reduce the disease burden.Hypertensive hazardness and patient's blood pressure level mutually outside the Pass, also depend on the situation of the other diseases of simultaneous other cardiovascular risk factors, target organ damage and merging.Therefore in hypertensive definition and classification, by hypertensive diagnostic criteria fix on systolic pressure >=140mmHg and (or) diastolic pressure >=90mmHg, according to blood pressure level, be divided into normally, outside normal high value blood pressure and 1,2,3 grade of hypertension, also according to the other diseases of risk factor, target organ damage and merging simultaneously, carry out risk stratification simultaneously.
Prevalence of Hypertension raises with age growth; Women's prevalence before climacteric, a little less than the male, but raises rapidly after climacteric, even higher than the male; High latitude cold district prevalence is higher than the warm area of low latitudes, and high altitude localities is higher than low altitude area; Relevant with dietary habit, salt and saturated fat are taken in higher, and mean blood pressure level and prevalence are also higher.Population of China hypertension is popular two relatively outstanding features: from south to the north, Prevalence of Hypertension is and increases progressively trend; Between different nationalities, Prevalence of Hypertension also has some differences, the national prevalence of living in the north or highlands is higher, the national prevalence of living in south or non-highlands is lower, this species diversity may be relevant with geographical environment, life style etc., not yet finds between various nationalities to have obvious genetic background difference.
Treating hypertensive main purpose is to reduce to greatest extent cardiovascular and cerebrovascular vessel morbidity and dead total danger, therefore require the doctor in the hypertensive while for the treatment of, intervene the clinical disease that all reversibility cardiovascular risk factors of patient, target organ damage and merging exist.For general hyperpietic's blood pressure lowering target, be below 140/90mmHg, for high-risk patients such as complication with diabetes or nephropathy, blood pressure should be taken the circumstances into consideration to be down to more low-level in the tolerant situation of patient.
Common depressor has: the Chinese medicine for lowering high blood pressure medicines such as calcium antagonists, RAS depressant, receptor,β blocking agent, diuretic antihypertensive medicine, Niuhuang Jiangya sheet.
Summary of the invention
The object of the present invention is to provide the antihypertensive purposes of Ke Nuoxin (CAS:6877-32-3).
Further, be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.
Ke Nuoxin can effectively reduce blood pressure, and controls preferably the systolic pressure of spontaneous hypertensive rat (SHR).
The specific embodiment
Embodiment 1. Ke Nuoxin hypotensive activities
10～13 week spontaneous hypertensive rats in age (SHR) are pressed to the blood pressure grouping, and concrete dosage is in Table 1, and oral administration is the arteria caudalis pressure measurement after 7 days.
Statistical analysis: measurement data mean+SD
Mean t check between relatively employing group of data between two groups.Take P<0.05 is the significance standard.
Result: Ke Nuoxin can effectively reduce the SHR rat blood pressure, and relatively there were significant differences (P<0.05) with model control group, in Table 1.
The impact of table 1. Ke Nuoxin successive administration on the SHR rat blood pressure
With model control group, compare
△P<0.05.
Claims (2)
1. the purposes of Ke Nuoxin, is characterized in that: the purposes of Ke Nuoxin antihypertensive function.
2. the purposes of Ke Nuoxin according to claim 1, is characterized in that: be used to preventing and treating the compositions of the hypertensive Ke Nuoxin of containing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103949131A CN103405430A (en) | 2013-09-03 | 2013-09-03 | Applications of corynoxine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103949131A CN103405430A (en) | 2013-09-03 | 2013-09-03 | Applications of corynoxine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103405430A true CN103405430A (en) | 2013-11-27 |
Family
ID=49598505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103949131A Pending CN103405430A (en) | 2013-09-03 | 2013-09-03 | Applications of corynoxine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405430A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342259A (en) * | 2008-06-18 | 2009-01-14 | 沈阳药科大学 | Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof |
| CN101862304A (en) * | 2010-07-23 | 2010-10-20 | 贵州百花医药股份有限公司 | Uncaria sustained-release tablet and preparation method thereof |
| CN102311435A (en) * | 2011-07-05 | 2012-01-11 | 南京泽朗农业发展有限公司 | Preparation method for high purity rhynchophylline |
| WO2012126390A1 (en) * | 2011-03-23 | 2012-09-27 | Hong Kong Baptist University | Autophagy inducing compound and use thereof |
-
2013
- 2013-09-03 CN CN2013103949131A patent/CN103405430A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342259A (en) * | 2008-06-18 | 2009-01-14 | 沈阳药科大学 | Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof |
| CN101862304A (en) * | 2010-07-23 | 2010-10-20 | 贵州百花医药股份有限公司 | Uncaria sustained-release tablet and preparation method thereof |
| WO2012126390A1 (en) * | 2011-03-23 | 2012-09-27 | Hong Kong Baptist University | Autophagy inducing compound and use thereof |
| CN102311435A (en) * | 2011-07-05 | 2012-01-11 | 南京泽朗农业发展有限公司 | Preparation method for high purity rhynchophylline |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103920025A (en) | Pharmaceutical composition for treating hypertension and application thereof | |
| CN103417537A (en) | Purpose of dehydrogenation hirsutine | |
| CN103520194A (en) | Novel application of jujuboside A | |
| CN104740336A (en) | Dendrobium officinale leaf extract with blood pressure reducing effect and application of dendrobium officinale leaf extract | |
| Posternak et al. | Angiotensin II blockade in normal man: interaction of renin and sodium in maintaining blood pressure | |
| CN104013631A (en) | New use of cylindrin | |
| CN103405461A (en) | Applications of salicin | |
| CN103432122A (en) | Application of isocorynoxeine in preparation of antihypertensive drugs | |
| CN103405430A (en) | Applications of corynoxine | |
| CN103446172A (en) | Application of fructus camptothecae acuminatae extractive vincoside lactam | |
| CN103479763B (en) | Traditional Chinese medicine composition for treating borderline hypertension and preparation method thereof | |
| CN104666512A (en) | Traditional Chinese medicine for treating hypertension | |
| CN102920815A (en) | Application of active parts of gambir plant total alkaloids | |
| CN104490982B (en) | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof | |
| Marzano | Primary aldosteronism and coronary-pulmonary artery fistula: coincidence or causal link? A case report and literature review | |
| BURRAGE et al. | Adrenal medullary tumor (pheochromocytoma); case report with successful operation | |
| CN103800307A (en) | Medicinal composition for reducing blood pressure and preparation method thereof | |
| CN104042604A (en) | New application of isomangiferin | |
| CN104758860B (en) | A kind of Chinese medicine composition for treating allergic rhinitis Asthma Syndrome | |
| CN102000187A (en) | Hypertension relieving traditional Chinese medicinal compound preparation and hypertension relieving insoles | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof | |
| CN101869567A (en) | Medicament composition containing biguanide antidiabetic medicament and sartan antihypertensive medicament and applications thereof | |
| CN105311269A (en) | Traditional Chinese medicine preparation capable of reducing blood sugar and preparation method thereof | |
| CN104027331A (en) | New use of coixol in reduction of blood pressure | |
| 刘慧玲 et al. | The relationship between CDK13 and TBAD patients undergoing TEVAR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131127 |